Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 15 studies | 33% ± 20% | |
peripheral blood | 12 studies | 23% ± 5% | |
lung | 10 studies | 19% ± 5% | |
eye | 6 studies | 25% ± 13% | |
kidney | 5 studies | 18% ± 2% | |
adipose | 4 studies | 28% ± 12% | |
bone marrow | 3 studies | 21% ± 4% | |
liver | 3 studies | 24% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 5877.23 | 1445 / 1445 | 100% | 50.88 | 183 / 183 |
kidney | 100% | 6250.03 | 89 / 89 | 100% | 166.43 | 901 / 901 |
lung | 100% | 6074.99 | 578 / 578 | 100% | 62.87 | 1155 / 1155 |
ovary | 100% | 5000.05 | 180 / 180 | 100% | 60.63 | 430 / 430 |
brain | 100% | 5232.53 | 2640 / 2642 | 100% | 109.28 | 705 / 705 |
thymus | 100% | 6738.35 | 653 / 653 | 100% | 95.96 | 604 / 605 |
breast | 100% | 7319.83 | 459 / 459 | 100% | 95.17 | 1114 / 1118 |
prostate | 100% | 5438.94 | 244 / 245 | 100% | 98.68 | 502 / 502 |
adrenal gland | 100% | 7168.30 | 258 / 258 | 100% | 76.74 | 229 / 230 |
uterus | 100% | 5951.50 | 170 / 170 | 99% | 53.09 | 454 / 459 |
bladder | 100% | 6494.00 | 21 / 21 | 99% | 54.10 | 498 / 504 |
stomach | 100% | 5069.73 | 359 / 359 | 99% | 44.04 | 282 / 286 |
intestine | 100% | 5990.69 | 966 / 966 | 98% | 41.46 | 516 / 527 |
pancreas | 98% | 2742.82 | 320 / 328 | 99% | 59.90 | 176 / 178 |
skin | 100% | 4537.95 | 1807 / 1809 | 96% | 58.77 | 453 / 472 |
liver | 100% | 2930.38 | 226 / 226 | 96% | 46.83 | 389 / 406 |
adipose | 100% | 7912.14 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 7438.61 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 41.78 | 29 / 29 |
muscle | 100% | 6524.23 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 5970.71 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 53.86 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 35.89 | 1 / 1 |
peripheral blood | 100% | 15749.78 | 927 / 929 | 0% | 0 | 0 / 0 |
heart | 97% | 4438.28 | 831 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 91% | 40.71 | 73 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0045732 | Biological process | positive regulation of protein catabolic process |
GO_0016567 | Biological process | protein ubiquitination |
GO_0031146 | Biological process | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process |
GO_0060586 | Biological process | multicellular organismal-level iron ion homeostasis |
GO_0006879 | Biological process | intracellular iron ion homeostasis |
GO_0019005 | Cellular component | SCF ubiquitin ligase complex |
GO_0000151 | Cellular component | ubiquitin ligase complex |
GO_0005829 | Cellular component | cytosol |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0051537 | Molecular function | 2 iron, 2 sulfur cluster binding |
GO_0005506 | Molecular function | iron ion binding |
GO_0005515 | Molecular function | protein binding |
Gene name | FBXL5 |
Protein name | F-box and leucine rich repeat protein 5 F-box/LRR-repeat protein 5 (F-box and leucine-rich repeat protein 5) (F-box protein FBL4/FBL5) (p45SKP2-like protein) |
Synonyms | FBL5 FLR1 FBL4 |
Description | FUNCTION: Component of some SCF (SKP1-cullin-F-box) protein ligase complex that plays a central role in iron homeostasis by promoting the ubiquitination and subsequent degradation of IREB2/IRP2 . The C-terminal domain of FBXL5 contains a redox-sensitive [2Fe-2S] cluster that, upon oxidation, promotes binding to IRP2 to effect its oxygen-dependent degradation . Under iron deficiency conditions, the N-terminal hemerythrin-like (Hr) region, which contains a diiron metal center, cannot bind iron and undergoes conformational changes that destabilize the FBXL5 protein and cause its ubiquitination and degradation . When intracellular iron levels start rising, the Hr region is stabilized . Additional increases in iron levels facilitate the assembly and incorporation of a redox active [2Fe-2S] cluster in the C-terminal domain . Only when oxygen level is high enough to maintain the cluster in its oxidized state can FBXL5 recruit IRP2 as a substrate for polyubiquination and degradation . Promotes ubiquitination and subsequent degradation of the dynactin complex component DCTN1 . Within the nucleus, promotes the ubiquitination of SNAI1; preventing its interaction with DNA and promoting its degradation . Negatively regulates DNA damage response by mediating the ubiquitin-proteasome degradation of the DNA repair protein NABP2 . . |
Accessions | ENST00000507899.1 ENST00000510802.5 D6R9Y4 ENST00000509314.5 D6RHC3 D6RCR7 ENST00000511441.5 D6RB50 ENST00000412094.6 [Q9UKA1-2] H0Y9Y0 D6RBW7 D6RED6 ENST00000503196.5 ENST00000515679.1 ENST00000513163.5 ENST00000341285.8 [Q9UKA1-1] H0YAG2 ENST00000512066.5 Q9UKA1 |